Wire · operational-macro
Grail rallies as FDA staff flags no major concerns for multi-cancer test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
FDA staff reviewers have raised no major concerns about Grail's multi-cancer blood test Galleri's accuracy and safety ahead of an advisory panel meeting to discuss premarket approval.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 10 sources have reported it between 21 Sep 2026 and 3 Oct 2026.
◆ ◆ The Wire takeaway
FDA signalling positive review for Galleri opens direct market access for approved tests beyond current lab regulations. Diagnostic test founders must prepare for rapid scale-up and insurance integration once approval arrives.
◆ Coverage
10 sources · first reported 21 Sep 2026 · latest 3 Oct 2026
◆ Related on Wire
◆ Topics